Dyax Readies HAE Therapy Kalbitor For Launch; Awareness Precedes Approval

Despite still awaiting FDA approval, Dyax is gearing up for the launch of its hereditary angioedema agent Kalbitor (ecallantide), focusing mainly on awareness and reimbursement issues